Diagnostic and Prognostic Salivary Biomarkers in Chronic Muscle Pain

NCT ID: NCT06994156

Last Updated: 2025-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A large proportion of the adult population worldwide currently lives with chronic muscle pain, with more than half of those affected experiencing pain localized to the face and jaw. This means that approximately 10-15% of the adult population is affected. Living with chronic muscle pain impacts many aspects of life, significantly affecting both the individual's quality of life and well-being as well as that of their close relations.

As with other chronic pain conditions, researchers agree that multiple factors contribute to the development and aggravation of the condition. The aim of this project is to identify proteins in saliva that are involved in the disease process of chronic muscle pain, in order to better understand the underlying mechanisms, improve prognosis assessment, and ultimately develop more effective treatments.

The project includes patients with localized chronic jaw muscle pain, those with generalized chronic pain (fibromyalgia), and pain-free individuals in a matched control group. Validated questionnaires are used to assess pain, including measures of physical and emotional function, followed by a clinical examination. Chewing-stimulated saliva is selected for sampling based on previous studies from the research group, and blood samples are collected from all participants. Proteins involved in metabolism, stress, and immunity will be analyzed, building on prior research conducted by the group. Patients will undergo conventional orofacial pain treatment and will later be followed up with new samples to study changes in protein expression following successful treatment.

Chronic muscle pain is one of the leading causes of work incapacity and long-term sick leave. This project combines clinical examinations with advanced biomedical analysis methods to investigate the role of specific proteins in disease development. The goal is to identify proteins involved in pain mechanisms to improve diagnostics and enable personalized treatments. In the short term, this could lead to faster and more accurate diagnoses and the development of new treatment strategies, which would reduce pain intensity and work incapacity, ultimately benefiting both individuals and society.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TMD/Orofacial Pain Fibromyalgia (FM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Muscle pain

Patients diagnosed with myogenious TMD and patients diagnosed with Fibromyalgia according to ACR 1990/2016

No interventions assigned to this group

Control

Matched healthy controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of myalgia or myofascial pain with referral according to the DC/TMD Axis I
* Diagnosis of fibromyalgia according to ACR 1990 or ACR 2016 criteria
* Minimum pain intensity of 30 on a 100 mm visual analogue scale (VAS)

Exclusion Criteria

* Diagnosed systemic muscular or joint diseases (except for fibromyalgia)
* Whiplash-associated disorder
* Migraine
* Neurological disorders
* Neuropsychiatric disorders
* Diseases of the salivary glands (e.g., sialadenitis, salivary gland tumours)
* Pregnancy and lactation
* Obesity
* Use of analgesics within the last 24 hours
* Oral complaints such as oral dryness
* Mucosal lesions in the oral cavity
* Fewer than 22 natural teeth
* Extensive prosthodontic rehabilitations
* Poor oral hygiene
* Hyposalivation
* Oral diseases (periodontal diseases and mucosal pain or ulcerations)
* Extensive dental abrasion
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eastmaninstitutet

OTHER

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hajer Jasim

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karolinska Institutet, Department of Dental Medicine

Stockholm, Huddinge, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DNR 2023-03570-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phenotype and Burden of a Midfacial Segment Pain
NCT06299995 ENROLLING_BY_INVITATION
Neurotropin Treatment of Fibromyalgia
NCT00366535 COMPLETED PHASE2